AstraZeneca, HutchMed's MET inhibitor Orpathys scores first global nod in China for rare lung cancer
23rd June 2021 Uncategorised 0 AstraZeneca, HutchMed’s MET inhibitor Orpathys scores first global nod in China for rare lung cancer
kdunleavy
Wed, 06/23/2021 – 10:47
More: AstraZeneca, HutchMed's MET inhibitor Orpathys scores first global nod in China for rare lung cancer
Source: fierce